Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system.


Journal

Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032

Informations de publication

Date de publication:
03 2019
Historique:
received: 05 11 2018
accepted: 02 01 2019
pubmed: 7 1 2019
medline: 24 10 2019
entrez: 7 1 2019
Statut: ppublish

Résumé

Molecular basis of abdominal pain in IBD is not fully characterized. Serotonin (5-HT) increases visceral pain severity and contributes to exacerbation of inflammation. Moreover, it is well established that decreased anandamide (AEA) signaling in the gut increases visceral pain severity. The aim of this study was to investigate the interplay between 5-HT and endocannabinoid signaling in colitis. We used 3% DSS in drinking water to induce colitis in mice. From day 3 5-HT was administered for 5 days and each day visceromotor response to colorectal distention (CRD) was measured. Expression of cannabinoid (CB) receptors as well as enzymes responsible of biosynthesis and degradation of endocannabinoids were investigated. Moreover, endocannabinoid levels were assessed by mass spectrometry. Additionally, we measured the expression of enzymes synthesizing 5-HT and AEA in the colon of IBD patients and healthy controls. Chronic exposure to 5-HT increased visceromotor response to CRD and worsened colitis, which was associated with decrease of AEA via 5-HT Our study shows a link between 5-HT and endocannabinoid signaling pathways in IBD. Thus, pharmacological blockade of 5-HT signaling or supplementation with endocannabinoids in the gut might be of benefit in severe cases of abdominal pain in IBD.

Sections du résumé

BACKGROUND AND AIMS
Molecular basis of abdominal pain in IBD is not fully characterized. Serotonin (5-HT) increases visceral pain severity and contributes to exacerbation of inflammation. Moreover, it is well established that decreased anandamide (AEA) signaling in the gut increases visceral pain severity. The aim of this study was to investigate the interplay between 5-HT and endocannabinoid signaling in colitis.
METHODS
We used 3% DSS in drinking water to induce colitis in mice. From day 3 5-HT was administered for 5 days and each day visceromotor response to colorectal distention (CRD) was measured. Expression of cannabinoid (CB) receptors as well as enzymes responsible of biosynthesis and degradation of endocannabinoids were investigated. Moreover, endocannabinoid levels were assessed by mass spectrometry. Additionally, we measured the expression of enzymes synthesizing 5-HT and AEA in the colon of IBD patients and healthy controls.
RESULTS
Chronic exposure to 5-HT increased visceromotor response to CRD and worsened colitis, which was associated with decrease of AEA via 5-HT
CONCLUSIONS
Our study shows a link between 5-HT and endocannabinoid signaling pathways in IBD. Thus, pharmacological blockade of 5-HT signaling or supplementation with endocannabinoids in the gut might be of benefit in severe cases of abdominal pain in IBD.

Identifiants

pubmed: 30611738
pii: S0006-2952(19)30001-2
doi: 10.1016/j.bcp.2019.01.001
pii:
doi:

Substances chimiques

Endocannabinoids 0
Serotonin 333DO1RDJY

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

37-51

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Maciej Salaga (M)

Department Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.

Agata Binienda (A)

Department Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.

Fabiana Piscitelli (F)

Endocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), Pozzuoli, Italy.

Anna Mokrowiecka (A)

Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.

Adam I Cygankiewicz (AI)

Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.

Roberta Verde (R)

Endocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), Pozzuoli, Italy.

Ewa Malecka-Panas (E)

Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.

Radzislaw Kordek (R)

Department of Pathology, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.

Wanda M Krajewska (WM)

Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.

Vincenzo Di Marzo (V)

Endocannabinoid Research Group, Institute of Biomolecular Chemistry (ICB), Pozzuoli, Italy; Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health, Quebec Heart and Lung Institute Research Centre and Institute of Nutrition and Functional Foods, Université Laval, Québec, Canada.

Jakub Fichna (J)

Department Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland. Electronic address: jakub.fichna@umed.lodz.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH